New cell culture plate eliminates edge effect during extended incubation
Thermo Scientific Nunc Edge 2.0 plate is designed to cost effectively increase cell consistency and productivity in cell-based assays.
A new 96-well plate is uniquely engineered to virtually eliminate evaporation during lengthy incubation, enabling full-plate usage and increased well-to-well cell consistency for improved productivity in cell culture assays at a cost comparable to a standard 96-well plate.
The Thermo Scientific Nunc Edge 2.0 96-Well Plate features a surrounding moat that, when filled with sterile water or media, serves as an evaporation barrier during extended incubation. As a result, edge effect and its associated risks of heterogeneous or biased results decrease. Even after long incubation periods of up to four days, the overall plate evaporation rate is reduced to less than two percent. More samples per plate can therefore be analyzed, increasing assay performance with potentially less cost and related product waste. Due to its large evaporation buffer zones, the next generation Nunc Edge 2.0 96-Well Plate is designed to eliminate well-to-well variability for optimal cell consistency across all of its 96 wells.
“When it comes to growing healthy, viable cells in extended microplate cultures, evaporation is a common yet significant challenge that researchers face,” explains Norman Yung, vice president and general manager, labware and specialty plastics at Thermo Fisher Scientific. “To minimize evaporation and mitigate its negative effects, researchers typically avoid using the outer wells of a standard 96-well plate, ultimately sacrificing 37.5% of the plate’s available real estate. With our new Edge 2.0 plate, scientists can reclaim full use of their plate without having to worry about edge effect. Researchers can also plan their experiments more efficiently and benefit from potential cost savings as a result of using and discarding fewer plates per experiment. We are also pleased to offer the new Edge 2.0 plate at a comparable price to a standard 96-well plate, enabling researchers to benefit from this innovation without compromising tight budgets.”
The new 96-well Edge 2.0 plate is available with both cell culture-treated and non-treated surfaces to suit an extensive range of lab applications. Untreated surfaces allow researchers to add the required coatings themselves, while also being hydrophobic and thus appropriate for growth of suspension cultures that can proliferate and grow without attachment. Conversely, the certified culture-treated option is designed to facilitate cell attachment and growth and is ideal for applications with adherent cell cultures.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance